The latest call
FetchingFortress Biotech, Inc. reported on 2026년 11월 13일. We are fetching the call transcript; its summary follows once the transcript is in.
기업 정보 불러오는 중
Just reported
From Fortress Biotech, Inc.'s results release of 2026년 11월 13일. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Actual
US$19.2M
+8.7% y/y
+2.4% q/q
Guided
—
No guide given
Actual
-US$7.2M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
| 항목 | 3개월 실적 (기준일)2026년 9월 30일 | 3개월 실적 (기준일)2025년 9월 30일 | 증감 |
|---|---|---|---|
| 총매출 | US$19.2M | US$17.6M | +8.67% |
| 순이익 | -US$5.8M | US$5.9M | -199.91% |
이것은 단일 분기 수치이며 최근 1년치가 아닙니다. 이 사이트의 다른 수치는 12개월을 다루므로 훨씬 큽니다. 계절성이 있는 사업은 둘 사이의 차이가 큽니다. 서비스나우는 12월 분기에 20억 달러의 잉여현금흐름을 벌지만 6월 분기에는 5억 달러입니다.
애널리스트 전망이 아니라 1년 전 같은 분기와 비교했습니다. “서프라이즈”나 “쇼크”를 말하려면 컨센서스 추정치가 필요한데, 이는 우리가 보유하지 않은 라이선스 데이터입니다. 잘못 말하는 것이 아예 말하지 않는 것보다 나쁩니다.
Fortress Biotech, Inc. reported on 2026년 11월 13일. We are fetching the call transcript; its summary follows once the transcript is in.
Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber Cancer Institute and Sentynl Therapeutics.
발표 자료 말미에 실린 기업 자신의 소개글입니다.
The quote, the company description and the latest quarter come from Fortress Biotech’s earnings press release (an Item 2.02 8-K) filed 2026년 11월 13일. Earlier quarters come from its quarterly and annual reports, and the latest will be replaced once the official report is filed. EDGAR에서 발표 자료 보기 주가는 액면분할과 배당을 반영해 조정했습니다.